Evidence map›Paper›PMID 31227855›Full record

ArticleRheumatology international2019

B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis.

Ioannis Antonopoulos, Dimitrios Daoussis, Maria-Eleni Lalioti, Theodora E Markatseli, Alexandros A Drosos, Stavros Taraviras, Andrew P Andonopoulos, Stamatis-Nick C Liossis

Abstract read
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. TFH cells in systemic sclerosis.Journal of translational medicine · 2021
    Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ioannis AntonopoulosDivision of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Rion, 26504, Patras, Greece.
Dimitrios DaoussisDivision of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Rion, 26504, Patras, Greece.
Maria-Eleni LaliotiDepartment of Physiology, School of Medicine, University of Patras, Rion, 26504, Patras, Greece.
Theodora E MarkatseliDepartment of Rheumatology, Ioannina University Hospital, University of Ioannina Medical School, Ioannina, Greece.
Alexandros A DrososDepartment of Rheumatology, Ioannina University Hospital, University of Ioannina Medical School, Ioannina, Greece.
Stavros TaravirasDepartment of Physiology, School of Medicine, University of Patras, Rion, 26504, Patras, Greece.
Andrew P AndonopoulosDivision of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Rion, 26504, Patras, Greece.
Stamatis-Nick C LiossisDivision of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Rion, 26504, Patras, Greece. snliossis@med.upatras.gr.ORCID http://orcid.org/0000-0003-2511-8083
University of Patras · GRUniversity of Ioannina · GR

Funding

"Karatheodori" unrestricted research grant of the University of Patras. D184
6 · The paper itself

Abstract

Recent data suggests that rituximab may favorably affect skin fibrosis and lung function in patients with systemic sclerosis. Based on experimental data suggesting a key role of B and T cells in scleroderma we aimed to explore the effect(s) of rituximab treatment on T cell subpopulations. Fifteen patients with scleroderma who received rituximab treatment and six who received standard treatment alone were recruited. Peripheral CD4+IL4+, CD4+INFγ+, CD4+IL17+ and CD4+CD40L+ T cells were assessed using flow cytometry. Using ELISA, serum levels of IL4 were assessed. Skin CD4+IL4+ T cells were assessed with confocal microscopy from skin biopsies. Following rituximab treatment skin CD4+IL4+ T cells obviously decreased as seen with confocal microscopy. Moreover, peripheral CD4+IL4+ T cells decreased significantly compared to those from patients who received standard treatment alone: median (IQR): 14.9 (22.63-12.88) vs 7.87 (12.81-4.9)%, p = 0.005 and 9.43 (19.53-7.50)% vs 14.86 (21.96-6.75)%, p = NS at baseline and 6 months later respectively, whereas there was no difference in serum IL4 levels. Peripheral CD4+CD40L+ T cells also decreased significantly following rituximab treatment compared to those from patients who received standard treatment alone: median (IQR): 17.78 (25.64-14.44)% vs 8.15 (22.85-3.08)%, p = 0.04 and 22.13 (58.77-8.20)% vs 72.11 (73.05-20.45)%, p = NS at baseline and 6 months later respectively. Furthermore, peripheral CD4+INFγ+ and CD4+IL17+ T cells revealed no differences following rituximab treatment. Our study demonstrates a link between rituximab treatment and CD4+IL4+ T cell decrease both in the skin and peripheral blood of patients with SSc.

Indexed as

AdultAgedAged, 80 and overCD40 LigandCD4-Positive T-LymphocytesFemaleHumansImmunologic FactorsInterleukin-4MaleMiddle AgedRituximabScleroderma, SystemicTreatment OutcomeCD40 LigandImmunologic FactorsInterleukin-4RituximabB cellsLymphocytesRituximabSclerodermaT cells

Identifiers

PMID31227855
OpenAlexW2950064282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.